What is the clinical evidence from this study?

Study design: Observational. Population: HER2 positive breast cancer (n=1139). Intervention: Trastuzumab vs. Non-trastuzumab. Primary outcome: Survival in early breast cancer (EBC) (HR 0.609, 95% CI 0.505-0.744).

What does this research mean for the field?

Trastuzumab therapy substantially improves survival compared to non-trastuzumab in both early and metastatic HER2-positive breast cancer, although its efficacy in metastatic disease is diminished if patients received adequate trastuzumab during the early stage. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

August 10, 2017The OncologistOpen Access

Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China

View Full Paper

Ask AI

Bookmark

Key result

Trastuzumab therapy substantially improved survival compared to non-trastuzumab in both early breast cancer (HR 0.609; 95% CI 0.505-0.744) and metastatic breast cancer (HR 0.541; 95% CI 0.418-0.606).

Authors

JLJianbin LiFujian Medical University SWShusen WangSun Yat-sen University YWYongsheng WangShandong University

Discussion

Member takes

Implication

Trastuzumab associated with improved survival in breast cancer; leaves open cardiac index effects amid low-certainty evidence against benefit.

Study Design

Type

Observational (n=1,139)

Multicenter

Yes

PICO

Population

HER2 positive breast cancer (n=1,139)

Intervention / Comparator

Trastuzumab vs Non-trastuzumab

Primary Outcome

Survival in early breast cancer (EBC) — HR 0.609 (0.505-0.744)

Main Result

Effect estimate: HR 0.609 (95% CI 0.505-0.744)

Cite This Study

Li et al. (2017) conducted an observational in HER2 positive breast cancer (n=1,139). Trastuzumab vs. Non-trastuzumab was evaluated on Survival in early breast cancer (EBC) (HR 0.609, 95% CI 0.505-0.744). Trastuzumab therapy substantially improved survival compared to non-trastuzumab in both early breast cancer (HR 0.609; 95% CI 0.505-0.744) and metastatic breast cancer (HR 0.541; 95% CI 0.418-0.606).

synapsesocial.com/papers/6a154dcb37103a43379f8742 https://doi.org/10.1634/theoncologist.2017-0088

View Full Paper

Ask AI

Bookmark

Implication

Trastuzumab associated with improved survival in breast cancer; leaves open cardiac index effects amid low-certainty evidence against benefit.

Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China

Discussion

Member takes

Implication

Study Design

PICO

Main Result

Cite This Study

Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China

Discussion

Member takes

Implication

Study Design

PICO

Main Result

Cite This Study

Also Consider

Also Consider